Search Results

There are 5181 results for: content related to: Re: Cabergoline versus levodopa monotherapy: A decision analysis

  1. Cabergoline for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Carl E Clarke and Katherine HO Deane

    Published Online : 22 JAN 2001, DOI: 10.1002/14651858.CD001518

  2. You have free access to this content
    Dopamine agonists for preventing ovarian hyperstimulation syndrome

    Intervention Review

    The Cochrane Library

    Huilin Tang, Selma Mourad, Suo-Di Zhai and Roger J Hart

    Published Online : 30 NOV 2016, DOI: 10.1002/14651858.CD008605.pub3

  3. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Carl E Clarke and Katherine HO Deane

    Published Online : 22 JAN 2001, DOI: 10.1002/14651858.CD001519

  4. Dopamine agonists for the treatment of restless legs syndrome

    Intervention Review

    The Cochrane Library

    Hanna Scholz, Claudia Trenkwalder, Ralf Kohnen, Levente Kriston, Dieter Riemann and Magdolna Hornyak

    Published Online : 15 MAR 2011, DOI: 10.1002/14651858.CD006009.pub2

  5. DA agonists - Ergot derivaties: Cabergoline

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S68–S71,

    Version of Record online : 29 JUL 2002, DOI: 10.1002/mds.5563

  6. Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal

    Clinical Endocrinology

    Volume 86, Issue 2, February 2017, Pages: 207–213, Shinya Watanabe, Hiroyoshi Akutsu, Shingo Takano, Tetsuya Yamamoto, Eiichi Ishikawa, Hiroaki Suzuki and Akira Matsumura

    Version of Record online : 11 OCT 2016, DOI: 10.1111/cen.13240

  7. Effect of grapefruit juice on cabergoline pharmacokinetics in patients with Parkinson's disease

    Clinical Pharmacology & Therapeutics

    Volume 77, Issue 2, February 2005, Page: P84, M. Nagai, A. Nakatsuka, H. Yabe, T. Moritoyo and M. Nomoto

    Version of Record online : 5 FEB 2005, DOI: 10.1016/j.clpt.2004.12.213

  8. THE EFFECT OF FOOD ON CABERGOLINE PHARMACOKINETICS AND TOLERABILITY IN HEALTHY VOLUNTEERS

    Biopharmaceutics & Drug Disposition

    Volume 17, Issue 5, July 1996, Pages: 443–455, S. Persiani, M. Rocchetti, M. A. Pacciarini, Beverly Holt, Steve Toon and Margherita Strolin-Benedetti

    Version of Record online : 5 MAY 1999, DOI: 10.1002/(SICI)1099-081X(199607)17:5<443::AID-BDD443>3.0.CO;2-U

  9. ORIGINAL ARTICLE: Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia

    Clinical Endocrinology

    Volume 73, Issue 3, September 2010, Pages: 369–374, Tricia Tan, Ines Z. Cabrita, Davina Hensman, Joanna Grogono, Waljit S. Dhillo, Kevin C. Baynes, Joseph Eliahoo, Karim Meeran, Stephen Robinson, Petros Nihoyannopoulos and Niamh M. Martin

    Version of Record online : 17 AUG 2010, DOI: 10.1111/j.1365-2265.2010.03827.x

  10. First Report for Electrochemical Determination of Levodopa and Cabergoline: Application for Determination of Levodopa and Cabergoline in Human Serum, Urine and Pharmaceutical Formulations

    Electroanalysis

    Volume 26, Issue 4, April 2014, Pages: 796–806, Somayeh Tajik, Mohammad Ali Taher and Hadi Beitollahi

    Version of Record online : 11 MAR 2014, DOI: 10.1002/elan.201300589

  11. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study

    Clinical Endocrinology

    Volume 37, Issue 6, December 1992, Pages: 534–541, J. Webster, G. Piscitelli, A. Polli, A. D'Alberton, L. Falsetti, C. Ferrari, P. Fioretti, G. Giordano, M. L'Hermite, E. Ciccarelli, P. G. Crosignani, L. DeCecco, R. Fadini, G. Faglia, F. Flamigni, G. Tamburrano, M. F. Scanlon and (European multicentre cabergoline dose-finding study group)

    Version of Record online : 17 MAR 2008, DOI: 10.1111/j.1365-2265.1992.tb01485.x

  12. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study

    Clinical Endocrinology

    Volume 68, Issue 1, January 2008, Pages: 66–71, Annamaria Colao, Roger Abs, David González Bárcena, Philippe Chanson, Wolfgang Paulus and David L. Kleinberg

    Version of Record online : 18 JUL 2007, DOI: 10.1111/j.1365-2265.2007.03000.x

  13. LONG-LASTING LOWERING OF SERUM GROWTH HORMONE AND PROLACTIN LEVELS BY SINGLE AND REPETITIVE CABERGOLINE ADMINISTRATION IN DOPAMINE-RESPONSIVE ACROMEGALIC PATIENTS

    Clinical Endocrinology

    Volume 29, Issue 5, November 1988, Pages: 467–476, C. FERRARI, A. PARACCHI, C. ROMANO, G. GEREVINI, M. BOGHEN, A. BARRECA, P. FORTINI and A. DUBINI

    Version of Record online : 17 MAR 2008, DOI: 10.1111/j.1365-2265.1988.tb03695.x

  14. You have full text access to this Open Access content
    Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume

    Reproductive Medicine and Biology

    Volume 14, Issue 2, April 2015, Pages: 79–84, Tomoko Inoue, Shu Hashimoto, Hideyuki Iwahata, Keijiro Ito, Yoshiharu Nakaoka and Yoshiharu Morimoto

    Version of Record online : 11 NOV 2014, DOI: 10.1007/s12522-014-0198-9

  15. Comparison of the use of cabergoline and gonadotrophin to treat primary and secondary anoestrus in bitches

    Australian Veterinary Journal

    Volume 90, Issue 5, May 2012, Pages: 194–196, D Nak, Y Nak and G Simsek

    Version of Record online : 17 APR 2012, DOI: 10.1111/j.1751-0813.2012.00913.x

  16. A CYP3A4 inhibitor increased the effect of cabergoline in the treatment of Parkinson's disease

    Clinical Pharmacology & Therapeutics

    Volume 77, Issue 2, February 2005, Page: P82, A. Nakatsuka, M. Nagai, H. Yabe, T. Moritoyo and M. Nomoto

    Version of Record online : 5 FEB 2005, DOI: 10.1016/j.clpt.2004.12.204

  17. Secondary deterioration of visual field during cabergoline treatment for macroprolactinoma

    Clinical Endocrinology

    Volume 70, Issue 4, April 2009, Pages: 588–592, Gérald Raverot, Maud Jacob, Emmanuel Jouanneau, Brigitte Delemer, Alain Vighetto, Michel Pugeat and Françoise Borson-Chazot

    Version of Record online : 31 JUL 2008, DOI: 10.1111/j.1365-2265.2008.03364.x

  18. Accurate mass measurement at enhanced mass-resolution on a triple quadrupole mass-spectrometer for the identification of a reaction impurity and collisionally-induced fragment ions of cabergoline

    Rapid Communications in Mass Spectrometry

    Volume 17, Issue 6, 30 March 2003, Pages: 561–568, Gary Paul, Witold Winnik, Nicola Hughes, Hans Schweingruber, Rexford Heller and Alan Schoen

    Version of Record online : 7 FEB 2003, DOI: 10.1002/rcm.952

  19. Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial

    Movement Disorders

    Volume 22, Issue 5, 15 April 2007, Pages: 696–703, Claudia Trenkwalder, Heike Benes, Ludger Grote, Svenja Happe, Birgit Högl, Johannes Mathis, Gerda M. Saletu-Zyhlarz and Ralf Kohnen

    Version of Record online : 1 FEB 2007, DOI: 10.1002/mds.21401

  20. Cabergoline versus levodopa monotherapy: A decision analysis

    Movement Disorders

    Volume 18, Issue 8, August 2003, Pages: 898–905, Antje M. Smala, E. Annika Spottke, Olaf Machat, Uwe Siebert, Dieter Meyer, Rudolf Köhne-Volland, Martin Reuther, Janeen DuChane, Wolfgang H. Oertel, Karin B. Berger and Richard C. Dodel

    Version of Record online : 8 APR 2003, DOI: 10.1002/mds.10465